

- electrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1 diabetes mellitus. *Diabetes Research and Clinical Practice*, 67(3), 211–219.
- Lim, S., Oh, T. J., Dawson, J., & Sattar, N. (2020). Diabetes drugs and stroke risk: Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials. *Diabetes, Obesity and Metabolism*, 22(1), 6–15.
- Miles, S. H., Lane, L. W., Bickel, J., Walker, R. M., & Cassel, C. K. (1989). Medical ethics education: Coming of age. In *Academic Medicine* (Vol. 64, Issue 12, pp. 705–714). <https://doi.org/10.1097/00001888-198912000-00004>
- Moxey, P. W., Gogalniceanu, P., Hinchliffe, R. J., Loftus, I. M., Jones, K. J., Thompson, M. M., & Holt, P. J. (2011). Lower extremity amputations—a review of global variability in incidence. *Diabetic Medicine*, 28(10), 1144–1153.
- Parmaksız, İ. (2011). *Diyabet komplikasyonlarında ileri glikasyon son ürünleri (Derleme)*.
- Perego, C., Da Dalt, L., Pirillo, A., Galli, A., Catapano, A. L., & Norata, G. D. (2019). Cholesterol metabolism, pancreatic β -cell function and diabetes. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*.
- Pittenger, G. L., Mehrabyan, A., Simmons, K., Dublin, C., Barlow, P., & Vinik, A. I. (2005). Small fiber neuropathy is associated with the metabolic syndrome. *Metabolic Syndrome and Related Disorders*, 3(2), 113–121.
- Şahin, G., Dabak, M. R., Sezgin, G., Dolapçioğlu, C., Ahıskalı, E., & Bayramiçli, O. U. (2017). Relationship Between Autonomic Diabetic Neuropathy and Glycemic Control. *Ankara Medical Journal*, 17(4), 245–252.
- Satman, I., Omer, B., Tutuncu, Y., Kalaca, S., Gedik, S., Dinccag, N., Karsidag, K., Genc, S., Telci, A., & Canbaz, B. (2013). Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. *European Journal of Epidemiology*, 28(2), 169–180.
- Turner, R. C., Cull, C. A., Frighi, V., Holman, R. R., & Group, U. K. P. D. S. (UKPDS). (1999). Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). *Jama*, 281(21), 2005–2012.
- WHO. (n.d.). *Diabetes*. Retrieved April 19, 2020, from <https://www.who.int/news-room/fact-sheets/detail/diabetes>